Development and validation of a modified albumin –bilirubin grade and α-fetoprotein score (mALF score) for hepatocellular carcinoma patients receiving atezolizumab and bevacizumab
ConclusionThe mALF score can reliably predict the prognosis of HCC patients receiving Atez/Bev.
Source: Hepatology International - Category: Infectious Diseases Source Type: research
More News: Avastin | Bilirubin | Cancer & Oncology | Carcinoma | Hepatocellular Carcinoma | Infectious Diseases | Liver Cancer | Statistics | Study | Training | Universities & Medical Training